your speakers for our 2 events

Biography

Dr. Huebert received a B.Sc. (Honours) degree in Biochemistry from the University of Saskatchewan in Saskatoon in 1974. He went on to complete his Doctor of Philosophy in Biological Psychiatry in the Neuropsychiatric Research Unit of the Department of Psychiatry at the same University in 1980.

Following his formal training, he joined the Richardson Merrell Research Centre in Strasbourg, France in 1980 in the Pharmacokinetics Group of the Clinical Pharmacology Department. In 1996, Dr. Huebert transferred to the Aventis Research Centre in Bridgewater, NJ where he remained until joining 3-Dimensional Pharmaceuticals in 2001 as Director of the Analytical Chemistry and Pharmacokinetics Department. Since 2004, Dr. Huebert has been the Team Leader for Discovery ADME for East Coast Research and Early Development (EC RED).

Dr. Huebert’s efforts have been in the support of Discovery and Development research programs through the application of in vitro and in vivo experimentation and the Development of Clinical Candidates through Pharmacokinetic support of preclinical and clinical development programs. His initial interests in bioanalytical methodology and techniques and in vivo pharmacokinetics gradually developed in parallel with that of the industry to the investigation of in vitro techniques for the rapid prediction of pharmacokinetic parameters and the screening of large numbers of NCE’s as a substitute for in vivo experimentation. He is currently Team Leader for ADME for the US RED site of Johnson and Johnson PRD and continues his interests in the use of in vitro, in vivo and in silico techniques to accelerate the advancement of discovery research programs and their successful progression into the formal development process.

Abstract

Research strategies in LG and LO: Combining in vitro and in vivo ADME approaches

The discovery and development of new chemical entities and identification of novel drugs involves many disciplines, including the evaluation of pharmacokinetic and pharmaceutical properties. The approaches applied by many companies in the drug industry involve reliance on in vitro screening and in vivo evaluation. In order to enhance the efficiency of drug identification, a strategy involving both rapid in vitro and in vivo approaches as well as more detailed profiling to understand the controlling mechanisms of distribution and disposition is applied. This can lead along with in silico modeling approaches to an understanding of risk/benefit and an earlier appreciation of human pharmacokinetic behavior. The presentation will outline different in vitro and in vivo strategies as well as case histories of strategic applications.